Experimental gerontology · 2025
Blood neurofilament light chain in patients with multiple sclerosis: A systematic review and updated meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ebrahimi Rasoul, Seifi Mojtaba, Masouri Mohammad Mahdi, Ravari Nejad Melika, Azad Ghazal, Kabiri Amir Hossein, Noori Shokoofe
Аннотация
BACKGROUND: This study aims to thoroughly evaluate blood neurofilament light chain (NfL) levels in multiple sclerosis (MS) patients compared to controls and across various MS subtypes.
METHODS: We conducted a systematic search of PubMed and Web of Science up to February 20, 2025, focusing on studies that reported blood NfL levels in individuals with MS and in control groups. Effect sizes were determined using Hedges' g, applying a random effects model for significant heterogeneity (I2 > 50 %), and a fixed effects model otherwise.
RESULTS: From 1380 records, 68 studies with a total of 19,159 participants were included. Blood NfL levels were significantly higher in MS patients compared to controls (SMD = 0.78; 95 % CI [0.67, 0.89], p < 0.001; I2 = 87.29 %). We also found elevated NfL levels in all major MS subtypes: RRMS (SMD = 0.71; 95 % CI [0.52, 0.91], p < 0.001; I2 = 90.26 %), SPMS (SMD = 0.94; 95 % CI [0.60, 1.28], p < 0.001; I2 = 88.43 %), PPMS (SMD = 0.79; 95 % CI [0.16, 1.42], p = 0.01; I2 = 95.75 %), and combined PMS (SMD = 0.96; 95 % CI [0.79, 1.12], p < 0.001; I2 = 80.28 %) compared to controls. Also, GFAP levels were significantly higher in PMS than in RRMS.
CONCLUSIONS: Our findings highlight the potential of blood NfL as a useful biomarker for tracking disease progression and distinguishing MS subtypes. However, additional studies are essential to confirm its effectiveness in clinical settings (Graphical abstract).
METHODS: We conducted a systematic search of PubMed and Web of Science up to February 20, 2025, focusing on studies that reported blood NfL levels in individuals with MS and in control groups. Effect sizes were determined using Hedges' g, applying a random effects model for significant heterogeneity (I2 > 50 %), and a fixed effects model otherwise.
RESULTS: From 1380 records, 68 studies with a total of 19,159 participants were included. Blood NfL levels were significantly higher in MS patients compared to controls (SMD = 0.78; 95 % CI [0.67, 0.89], p < 0.001; I2 = 87.29 %). We also found elevated NfL levels in all major MS subtypes: RRMS (SMD = 0.71; 95 % CI [0.52, 0.91], p < 0.001; I2 = 90.26 %), SPMS (SMD = 0.94; 95 % CI [0.60, 1.28], p < 0.001; I2 = 88.43 %), PPMS (SMD = 0.79; 95 % CI [0.16, 1.42], p = 0.01; I2 = 95.75 %), and combined PMS (SMD = 0.96; 95 % CI [0.79, 1.12], p < 0.001; I2 = 80.28 %) compared to controls. Also, GFAP levels were significantly higher in PMS than in RRMS.
CONCLUSIONS: Our findings highlight the potential of blood NfL as a useful biomarker for tracking disease progression and distinguishing MS subtypes. However, additional studies are essential to confirm its effectiveness in clinical settings (Graphical abstract).